Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inventiva ( (IVA) ) has provided an announcement.
On November 6, 2025, Inventiva announced the total voting rights and shares forming its share capital as of October 20, 2025. The company reported 145,951,274 shares outstanding with 158,653,570 gross voting rights and 158,594,019 net voting rights. This update is crucial for stakeholders as it informs them about the company’s governance structure and potential influence at shareholder meetings.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating patients with MASH, a chronic liver disease. The company is publicly listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 159,852
Technical Sentiment Signal: Buy
Current Market Cap: $616.8M
See more insights into IVA stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “We Need to Improve Windows in Ways That are Meaningful to People”: Microsoft Stock (NASDAQ:MSFT) Slips as it Rebuilds Trust in Windows
- “Forget the Tesla You Knew,” Tesla Stock (NASDAQ:TSLA) Blasts Up on Huge Capex Plan
- “Our Point of Differentiation”: Starbucks Stock (NASDAQ:SBUX) Slides as the Cafe is About More Than a Third Place